Research programme: diabetes therapeutics - Arena Pharmaceuticals

Drug Profile

Research programme: diabetes therapeutics - Arena Pharmaceuticals

Alternative Names: GPR119 agonists - Arena Pharmaceuticals; JNJ-28630355

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arena Pharmaceuticals
  • Class Pyrimidines; Small molecules
  • Mechanism of Action G protein-coupled receptor agonists; GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
  • 10 Mar 2011 Research programme: diabetes therapeutics - Arena Pharmaceuticals is available for licensing. http://www.arenapharm.com
  • 09 Nov 2010 Ortho-McNeil-Janssen Pharmaceuticals announces termination of its collaboration with Arena Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top